(Q33366541)

26 July 2017

1 reference

title

Synthetic heparin derivatives as new anticoagulant drugs (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

Martin de Kort

1

1 reference

26 July 2017

Rogier C Buijsman

series ordinal

2

1 reference

26 July 2017

Constant A A van Boeckel

series ordinal

3

1 reference

26 July 2017

publication date

1 June 2005

1 reference

26 July 2017

1 reference

26 July 2017

volume

10

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

769-779

1 reference

2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-O-sulfo-alpha-D-glucopyranosyl)-(1-4 )-O-(beta-D-glucopyranosyluronic acid)-(1-4)-O-(2-deoxy-2-sulfamido-3,6-di-O-sulfo-alpha-D-glu copyranosyl)-(1-

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

A mechanism for heparin-induced potentiation of antithrombin III

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

The Influence of Hinge Region Residue Glu-381 on Antithrombin Allostery and Metastability

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

The anticoagulant activation of antithrombin by heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Crystal structure of antithrombin in a heparin-bound intermediate state

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Mechanisms of glycosaminoglycan activation of the serpins in hemostasis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Regulation of thrombin activity by antithrombin and heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

First Synthetic Carbohydrates with the Full Anticoagulant Properties of Heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Identification of a hexasaccharide sequence able to inhibit thrombin and suitable for 'polymerisation'.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Experimental Proof for the Structure of a Thrombin-Inhibiting Heparin Molecule

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

New synthetic heparin mimetics able to inhibit thrombin and factor Xa.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Synthesis of thrombin-inhibiting heparin mimetics without side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Design and evaluation of novel bivalent thrombin inhibitors based on amidinophenylalanines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Design and synthesis of a novel synthetic NAPAP-penta-saccharide conjugate displaying a dual antithrombotic action.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Direct thrombin inhibitors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Designing small, nonsugar activators of antithrombin using hydropathic interaction analyses.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

An overview of the heparin-induced thrombocytopenia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

The structure of a complex of recombinant hirudin and human alpha-thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903457-4

7 January 2021

10.1016/S1359-6446(05)03457-4

Identifiers

DOI

1 reference

26 July 2017

1 reference